Letter to the Editor
Continuous subcutaneous insulin infusion (CSII) is widely used in the United States; 1 however, the percentage of CSII usage among type 1 diabetes mellitus (T1DM) patients in Japan has been unclear. We performed a cross-sectional study of CSII usage among T1DM patients at 11 National Hospital Organization (NHO) hospitals in Japan.
The survey was conducted complying the regulations of NHO that obtain informed consent from all the patients allowing the statistical analysis of the medical records on condition that the privacy of the patients is strictly protected, unless the patients opt out. 2 The medical records of 493 adult T1DM patients were analyzed. The percentage of CSII usage was investigated, and the characteristics of subjects using CSII and subjects using multiple daily injections (MDI) were compared. The percentages of CSII usage between different age groups (age group 1: 18-24 years old, age group 2: 25-64 years old, age group 3: 65+ years old) were also compared. The survey was conducted between April 2010 and March 2012. Data were analyzed using the Statistical Package for Social Science software version 20.0 (SPSS Inc, Chicago, IL, USA).
The characteristics of subjects using MDI and subjects using CSII are described in Table 1 . The mean age of the patients was 48.7 years old (SD 17.0 years), and 57.0% were female. The percentage of CSII usage was 15.0%. Compared to subjects using MDI, subjects using CSII were younger (MDI: 50.1 ± 17.2 years old vs CSII: 40.5 ± 13.1 years old; P < .01), and female dominant (MDI: 54.2% vs CSII: 73.0%; P < .01). There was no significant difference in the mean HbA1c levels (MDI: 8.4 ± 1.6% vs CSII: 8.1 ± 1.6%; P = .27). The percentage of CSII usage was significantly higher in age group 1 and was significantly lower in age group 3 (23.5% in age group 1, 17.1% in age group 2, 4.1% in age group 3, P = .002).
To our knowledge, this is the first multicenter survey of the percentage of CSII usage among T1DM patients in Japan. The percentage of CSII usage was low and CSII was more commonly used in younger adults and less commonly used in elderly adults. The mechanism why CSII usage was low in Japan needs to be addressed in future study. One hypothesis is that, due to the legal requirements in Japan, insulin pump manufacturers are not allowed to send their pump trainers to medical institutes or patients directly, and this restriction might be a barrier to more frequent usage of insulin pump. The reason why there was no significant difference in the HbA1c levels between CSII and MDI in this survey also remains unclear. In another small study conducted in Japan, the HbA1c levels of T1DM patients using CSII were significantly lower than those using MDI. 3 There might be difference in the insulin pump education or patient background between different medical institutions. We need to note the presented data are 5 to 7 years old and might or might not be accurate at this time. In 2015, the sensor-augmented pump became commercially available in Japan, and further study is needed to follow up the usage of CSII.
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